Developing solutions for people with mental illness
Janssen has a long tradition of research into mental illness. For more than 50 years, our unwavering commitment to mental health has led to innovative products to treat schizophrenia, schizoaffective disorder, and bipolar disorder. We are also working on new products for Alzheimer’s disease, depression, and severe mood disorders.
As a business, we care deeply about the overall well-being of our patients and their families. Janssen is dedicated to shifting perceptions and eliminating the stigma of mental health issues. We do this by providing access, education, support, and treatment for individuals seeking help as well as to the general public.
We are proud of how we connect our community work in mental health with our sustainability goals by promoting public health and well-being, safeguarding the planet, keeping our business strong, and doing business in a responsible manner both now and in the future.
Breaking through the stigma
We support programs which strengthen health systems and reduce the societal impact and stigma attached to mental illness. This helps us to draw attention to our vision on mental health around the world. Along with the communities which we serve, we embrace a future for people living with mental illness which is stigma-free and includes access to optimal care.
It is estimated that there were 35.6 million people with dementia, including Alzheimer’s disease, worldwide in 2010. This number is likely almost to double every 20 years, increasing to 65.7 million in 2030 and 115.4 million in 2050.
Janssen is committed to education and awareness building on dementia. One example of this is the website Dementia.com. The website provides dementia patients, healthcare workers, and family members with information on the causes, symptoms, and treatments for dementia. We also offer guides on preventative care and help people to differentiate age-related memory loss from memory loss through the more severe impact of neurodegenerative diseases such as Alzheimer’s.